Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Somatrogon (MOD-4023) vs Daily Genotropin in Japanese Pre-pubertal Children With Growth Hormone Deficiency
jRCT2080223906Phase 3Completed
- Sponsor
- OPKO Health
- Start
- May 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of somatrogon in growth hormone deficiency (GHD) (2 arms), sponsored by OPKO Health. Primary endpoint: Annual growth rate at 12 months. Started May 2018; status: completed.
02
Drugs
somatrogon
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on jRCT2080223906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223906.